anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The classification of mental, behavioural and neurodevelopmental disorders in the World Health Organization's International Classification of Diseases 11th revision (ICD-11) includes a comprehensive set of behavioural indicators (BIs) within the neurodevelopmental disorders grouping. BIs can be used to assess the severity of disorders of intellectual development in situations in which standardised measures of intellectual functioning and adaptive behaviours are not available or feasible. This international study examines the implementation characteristics of the BIs and compares them to standardised measures for assessing the severity of intellectual impairment and adaptive behaviours in disorders of intellectual development and autism spectrum disorder (ASD). The clinical utility of the ICD-11 and the fidelity of its application in international clinical settings were also assessed.
METHODS: A total of 116 children and adolescents (5-18 years old) with a suspected or established diagnosis of disorders of intellectual development were included across four sites [Italy (n = 18), Sri Lanka (n = 19) and two sites in India (n = 79)]. A principal component analysis was conducted to evaluate the application of the ICD-11 guidance for combining severity levels.
RESULTS: Assessment using the BIs showed a higher proportion of individuals classified with mild severity, whereas the standardised measures indicated a higher proportion of severe ratings. Additionally, individuals with co-occurring ASD tended to have more severe impairments compared with those without ASD, as indicated by both BIs and standardised measures. Overall, the BIs were considered clinically useful, although more time and consideration were required when applying the guidelines for individuals with a co-occurring disorder of intellectual development and ASD. The principal component analysis revealed one principal component representing overall disorders of intellectual development severity levels.
CONCLUSIONS: The ICD-11 BIs can be implemented as intended in international clinical settings for a broad range of presentations of individuals with neurodevelopmental disorders. Use of the BIs results in similar severity diagnoses to those made using standardised measures. The BIs are expected to improve the reliability of severity assessments in settings where appropriate standardised measures for intellectual and adaptive behaviours are not available or feasible.
The present invention relates to a traditional Chinese medicine for curing diseases such as thrombus, nerve, rheumatism, etc., particularly a traditional Chinese medicine preparation for dispelling rheumatism and cold, nourishing the heart, tranquilizing, activating blood, removing stasis, and resuscitating and freeing the orifices. The traditional Chinese medicine preparation is developed to mainly solve the problems of narrow range of treatment, long course of treatment, poor curative effect, etc. of the existing traditional Chinese medicine preparations. The present invention is prepared from 39 kinds of traditional Chinese medicines such as wild aconite, radix aconiti, henbane seed, nux vomica, arisaema root, giant typhonium herb, giant typhonium rhizome, muskroot-like semiaquilegia root, asparagus root, euphorbia helioscopia, clematis root, etc. The prescription of the present invention has medicines used for stanching, relieving coughs, reducing sputum, relieving pains, expelling intestinal parasites, promoting urination, and softening and resolving hard masses. Besides, the present invention has the functions of dispelling rheumatism and cold, nourishing the heart, tranquilizing, activating blood, removing stasis, clearing away heat, detoxifying, suppressing hyperactive liver for calming endogenous wind, resuscitating and freeing the orifices, etc.
Adverse reactions observed with terbutaline sulfate injection are similar to those commonly seen with other sympathomimetic agents. All these reactions are transient in nature and usually do not require treatment. The following table compares adverse reactions seen in patients treated with terbutaline sulfate injection (0.25 mg and 0.5 mg), with those seen in patients treated with epinephrine injection (0.25 mg and 0.5 mg), during eight double-blind crossover studies involving a total of 214 patients.

Note: Some patients received more than one dosage strength of terbutaline sulfate and epinephrine. In addition, there were reports of anxiety, muscle cramps, and dry mouth (<0.5%). There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis with terbutaline administration.

To report SUSPECTED ADVERSE REACTIONS, contact Areva Pharamceuticals Inc. at 1-855-853-4760 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
We utilized the silkworm ( Bombyx mori )/baculovirus system to produce recombinant Major Merozoite Surface Protein 1 (MSP1 42 ) because of the low cost and potential high yield of this expression system. The MSP1 42  (3D7 sequence) was cloned into the baculovirus, BmNPV with the melittin signal sequence. The recombinant virus, BmNPV-Sp42 was used to infect silkworms for the expression of MSP1 42  (Sp42). One recombinant clone expressed high level of Sp42 with an estimated 0.5 mg of antigen produced within a single worm. The Sp42 was recognized by monoclonal and polyclonal antibodies specific for parasite MSP1 in direct binding and competitive binding ELISAs, suggesting that Sp42 possesses antigenic determinants similar to parasite MSP1 42 . Immunogenicity studies were performed in rabbits. Sp42 induced high titers of antibodies crossreactive with MSP1. Specificity analyses showed that anti-Sp42 antibodies reacted primarily against conserved determinants on MSP1-19. Our results showed that the silkworm expression system can produce recombinant MSP1 42  that are antigenically and immunogenically comparable to other recombinant MSP1 antigens expressed in other eukaryotic systems. The low cost ad high level of protein expression makes it an attractive alternative for the development of a human malaria vaccine.
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.
Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence is a physiological state in which the body adapts to the drug after a period of regular exposure, resulting in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.

Do not abruptly discontinue Benzhydrocodone and Acetaminophen Tablets in a patient physically dependent on opioids. Rapid tapering of Benzhydrocodone and Acetaminophen tablets in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing Benzhydrocodone and Acetaminophen tablets , gradually taper the dosage using a patient-specific plan that considers the following: the dose of Benzhydrocodone and Acetaminophen tablets the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for a long duration at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [ see Dosage and Administration (2.6), Warnings and Precautions (5.16)]. 

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [ see Use in Specific Populations (8.1)].
Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
Disclosed is a composition of matter that features a liquid biocatalyst to stimulate biological activity. The composition is both environmentally and physically safe. The biological simulators in the inventive biocatalyst increase the metabolic and reproductive rates of most bacteria. Its introduction into a waste water treatment system non-selectively enhances aerobic biological activity, thereby improving both carbonaceous and nitrogenous removals. The product is especially effective for endogenous situations. The non-selective nature of the product enhances most biological activity, thus allowing for overall performance improvements within a treatment plant. The inventive composition of matter is made by the blending of Ascophyllum nodosum seaweed extract, Liquid Coconut Oil Soap, Vitamin Mixture, and De-ionized water. Ascophyllum nodosum seaweed is preferably extracted from freshly harvested ascophyllum nodosum seaweed. The soap is a highly concentrated, versatile product made up of liquid coconut oil that is dispersing agent that acts as a lubricant or release agent. The vitamin mixture is used to supply the missing intra-cellular enzymes that are required for maximum cellular metabolism and utilization of the organic material in the waste water. These substances are very low or nonexistent in the normal waste water, industrial effluents and in most natural water environments.
Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
Tablets or granules are coated by applying thereto a solution of ethyl cellulose and a polyalkylene glycol in a solvent comprising a mixture of a volatile aliphatic alcohol and a volatile chlorinated aliphatic hydrocarbon, and then evaporating the said solvent. Suitable polyalkylene glycols have a molecule weight of at least 6000; alcohols may be methyl, ethyl, or iso propyl alcohol, and chlorinated hydrocarbons may be chloroform, methylene chloride, or 1,1,1-trichloroethane.  Other components which may be present in the coating solutions are opaque or coloured fillers, e.g. titanium dioxide, talc, or insoluble pigments such as aluminium lakes or iron oxides; water-proofing agents, e.g. paraffin wax or a hard fat; digestion-resistant substances such as high molecular weight fatty acids; and wax to give a polished coating.  The coating is suitably applied as a spray, the tablets being rotated in a coating pan in a curent of hot air, while the solvent vapours are removed by a vapour extraction system.
Obesity-related hypogonadotropic hypogonadism is a well-characterized condition in men (termed male obesity-related secondary hypogonadism; MOSH); however, an equivalent condition has not been as clearly described in women. The prevalence of polycystic ovary syndrome (PCOS) is known to increase with obesity, but PCOS is more typically characterized by increased gonadotropin-releasing hormone (GnRH) (and by proxy luteinizing hormone; LH) pulsatility, rather than by the reduced gonadotropin levels observed in MOSH. Notably, LH levels and LH pulse amplitude are reduced with obesity, both in women with and without PCOS, suggesting that an obesity-related secondary hypogonadism may also exist in women akin to MOSH in men. Herein, we examine the evidence for the existence of a putative non-PCOS "female obesity-related secondary hypogonadism" (FOSH). We précis possible underlying mechanisms for the occurrence of hypogonadism in this context and consider how such mechanisms differ from MOSH in men, and from PCOS in women without obesity. In this review, we consider relevant etiological factors that are altered in obesity and that could impact on GnRH pulsatility to ascertain whether they could contribute to obesity-related secondary hypogonadism including: anti-Müllerian hormone, androgen, insulin, fatty acid, adiponectin, and leptin. More precise phenotyping of hypogonadism in women with obesity could provide further validation for non-PCOS FOSH and preface the ability to define/investigate such a condition.
The research was conducted with randomized control, pretest-posttest, experimental, and control group design. By using G\*Power analysis, it was determined that the experimental group of the nurse managers was 30 people and included randomly in the sample calculation of the study. The experimental group was given 2 days of problem-solving and decision-making training. Before the training, the nurse administrators in the experimental group were administered the Participant Information Form-Nurse Manager, PSI, DMSS and two Case Evaluation Forms and Problem Solving and Decision Making Information Form-Pre-Test-Post-Test.
1. The aim of this study was to estimate heritability and genetic correlations, first among behavioural responses of juvenile South African Black ostriches towards humans and secondly with slaughter weight and skin traits.2. Behavioural traits, such as willingness of the birds to approach humans, keeping a distance from the human observer and allowing touch interactions by a human were recorded (n = 1012 birds). In addition, slaughter weight, skin size, scores for nodule size, nodule shape and the presence of hair follicles were recorded.3. Single- and multi-trait animal model analyses performed on the data using ASReml4 revealed high heritability estimates of 0.44 for allowing touch interactions and 0.48 for both willingness to approach and keeping a distance from the human observer. In addition, significant genetic correlations among behavioural response traits were estimated, ranging from -0.99 between keeping a distance and willingness to approach the human observer, to 0.87 between allowing touch interactions and willingness to approach the human observer.4. In contrast, genetic correlations of behavioural response traits with most slaughter and skin traits were low, variable, and not significant. The exception was hair follicle score, which appeared to be unfavourably correlated with key behavioural traits.5. This study suggested that the temperament of ostriches could be improved by selection of birds that demonstrate willingness to associate with humans without compromising slaughter weight or skin traits.
Neurocognitive impairments, or problems with thinking and brain function, are a core component of schizophrenia. Such impairments, which can range from moderate to severe, are strongly associated with decreased benefit from psychiatric rehabilitation and problems with treatment adherence, socialization, employment, quality of life, and relapse. Researchers believe that the failure of medication to improve cognition may occur because medication treatment lacks cognitive stimulation. Cognitive remediation programs are a way to provide that stimulation, and they have shown moderate efficacy in improving cognition in people with schizophrenia. Implementing these cognitive remediation programs as part of schizophrenia treatment has occurred only at individual sites with highly trained research personnel. This study will test whether cognitive remediation programs for schizophrenia can be feasibly implemented at a network of sites that do not specialize in cognitive remediation research. This pilot study will gather preliminary efficacy data, but a larger study is required to draw definitive conclusions about treatment effects.

Participation in this study will last approximately 8 weeks. Participants will be randomly assigned to the Posit Science intervention group or the control group. Those in the Posit Science group will receive targeted cognitive training (TCT)-40 hours of adaptive computer exercises-and participate in a weekly bridging group that helps participants apply cognitive skills to everyday contexts. Length of the TCT may vary, depending on the availability of participants to complete the exercises. Those in the control group will play commercially available video games for the same number of hours and participate in a weekly health and wellness group. All participants will undergo assessments at baseline, mid-treatment, and post-treatment. Assessments will include self-report questionnaires and clinical interviews.
PURPOSE OF REVIEW: Acute myocardial infarction (AMI) is heralded by chronic inflammation and entails an excessive burst of acute-on-chronic inflammation (AoCI). This review describes the evolution from understanding atherosclerosis as a chronic inflammatory disease, to recent efforts in optimizing anti-inflammatory therapy to patients with AMI. It highlights the challenges and opportunities in selecting the optimal patient with AMI to derive maximal benefit from early anti-inflammatory therapy.
RECENT FINDINGS: The causal role of inflammation in atherosclerosis has been proven in large outcome trials. Since then, several smaller trials have sought to translate the concept of anti-inflammatory therapy targeting residual inflammatory risk to the dynamic early phase of AoCI after AMI. Current evidence highlights the importance of selecting patients with a high inflammatory burden. Surrogate criteria for large AMI (e.g., angiographic or electrocardiographic), as well as novel point-of-care biomarker testing may aid in selecting patients with particularly elevated AoCI. Additionally, patients presenting with AMI complicated by pro-inflammatory sequelae (e.g., atrial fibrillation, acute heart failure, left ventricular thrombosis) may dually profit from anti-inflammatory therapy.
SUMMARY: Improved understanding of the mechanisms and dynamics of acute and chronic inflammatory processes after AMI may aid the strive to optimize early anti-inflammatory therapy to patients with AMI.
AIM: This study aims to evaluate the impact of frailty on the outcomes of older patients with pulmonary embolism (PE).
METHODS: Using the National Inpatient Sample database, we identified 288 070 patients aged 65 or older who were admitted with a primary diagnosis of PE from 2017 to 2019. Frailty was assessed using the Hospital Frailty Risk Score (HFRS), and patients were categorized into low-, intermediate-, and high-frailty-risk groups. Multivariate logistic regression was used to calculate adjusted odds ratios for all outcomes.
RESULTS: These patients were categorized into low-risk (57.6%, 161 420), medium-risk (39.9%, 111 805), and high-risk (2.5%, 7075) groups. High-risk patients, predominantly females with multiple comorbidities, exhibited significantly higher mortality rates and adverse outcomes. The HFRS showed a good discriminating ability in predicting mortality (area under the receiver operating characteristic curve = 0.7796). Frailty was associated with increased use of advanced therapeutic interventions and critical care resources such as thrombolysis, catheter-directed therapies, inferior vena cava filter placement, mechanical ventilation, vasopressor use, and intensive care unit admission.
CONCLUSION: Frailty markedly affects outcomes in older PE patients. The HFRS offers a valuable prognostic tool in this population, suggesting that integrating frailty assessments into clinical practice could enhance care strategies and improve patient outcomes. Our findings underscore the need for further research to refine frailty-based care paradigms. Geriatr Gerontol Int 2024; 24: 924-929.
With the steady development of catheter ablation, it has gradually become the main treatment of various arrhythmias. Antithrombotic and anticoagulant therapy after catheter ablation determines the occurrence of perioperative bleeding and ischemic events. However, the incidence, characteristics and short-term prognosis of secondary acute cerebrovascular events in patients with arrhythmia after catheter ablation have not been studied. Methods: This study was intended to retrospectively collect and analyze the case data and auxiliary examination results of patients with arrhythmia who underwent catheter ablation. To evaluate the incidence, clinical features and short-term prognosis of secondary acute ischemic and hemorrhagic cerebrovascular events in patients with arrhythmia after catheter ablation. In order to improve the quality of life of patients, reduce the secondary acute cerebrovascular complications in the hospital in patients with arrhythmia after catheter ablation, to provide evidence for promoting the clinical management of such patients, and to provide help for the maximum degree of prevention and control risk.
The invention provides a system (100) a method (400) for Functional Neurosciences, Neuro modulation with advanced neurorehabilitation to assess, prognosticate and track nervous system recovery. The method (400) includes storing clinical data in a memory (203). The method (400) may further include training a Machine Learning (ML) model using the stored clinical data. The method (400) may further includes receiving a user input from one or more users. The method (400) may further includes determining a disease and stages of the disease using the trained AI & ML model. The method (400) may further includes suggesting (410) a treatment plan based on the determined disease and the trained machine learning model. Further, the method (400) includes outputting the suggested treatment plan via a user interface.
Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.